Second, by simultaneously engaging both LGR5 and EGFR, the antibody facilitates rapid endocytosis and degradation of EGFR in LGR5-positive tumor cells—a mechanism not observed in cetuximab [100]. This evidence concerns the gene LGR5 and neoplasm.